cytochrome P450 family 3 subfamily A member 52, pseudogeneGenealiases: []
Q-omics provides the consensus-scored CYP3A52P profile across patient tissues and cancer cell-line models. CYP3A52P expression is associated with patient survival in 16 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, CYP3A52P is differentially expressed in 2, with the highest sampling consensus in CHOL. Additionally, CYP3A52P RNA expression shows 7,215 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight LUAD, CHOL, and UVM as cancer lineages where CYP3A52P shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CYP3A52P — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CYP3A52P survival associations across molecular data types. CYP3A52P RNA expression shows survival associations in the most cancer types (16). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CYP3A52P RNA expression–survival associations across cancer types. High CYP3A52P expression shows favorable associations in LUAD, ESCA, BLCA, PAAD, UCS and CESC. The LUAD Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify LUAD as the clearest survival context for CYP3A52P RNA expression.
This table summarizes CYP3A52P tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for CYP3A52P. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CYP3A52P shows lower tumor expression in CHOL and higher tumor expression in KIRC. The CHOL box plot shows higher CYP3A52P RNA expression in normal versus tumor tissue (log2 FC = −0.804, t-test p = .004).
This table shows molecular features associated with CYP3A52P in patient tissues and cancer cell lines. In patient samples, CYP3A52P shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set.
